Moderate effect of GGCX polymorphisms on patients warfarin dosage requirement- a meta-analysis

Zhixing Luo1, Xi Li1, Mouze Liu1, Yan Shu1, Jiye Yin1, Xiaoping Chen1, Jianquan Luo1, Xiaobing Li2, Wei Zhang1,*

1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China
2 Department of Cardio-Thoracic Surgery, the Second Xiangya Hospital of Central South University, Middle Ren-Min Road No. 139, Changsha, Hunan 410011, P.R. China

Email address: yjsd2003@163.com (Wei Zhang), Dale75@126.com (Xiaobing Li)


Abstract: Objective: Association studies on the effects of GGCX gene polymorphisms on warfarin stable dose have shown conflicting results. The aim of this study is to quantitatively summarize whether GGCX gene polymorphisms have potential roles in warfarin dosage requirement. Methods: Publications were searched in PubMed, Medline and ISI Web of Knowledge and chosen by exact inclusion and exclusion criteria. A meta-analysis was conducted by using Revman 5.0 software to determine the association between common polymorphisms of the three genes and warfarin dose requirement. Results: Data were extracted from 13 publications with 4167 patients enrolled. Two common polymorphisms (rs699664, rs12714145) of GGCX were included for further meta-analyses. Comparing to rs699664AA genotype carriers, rs699664G/G genotypes carriers required higer 3% [95% CI: 2% - 4%, P-value < 0.0001] warfarin dose. The warfarin dosage requirement showed no significant difference between rs699664GG and rs699664GA genotype carriers, P=0.51. Compared to rs12714145AA carriers, the GG and GA genotype carriers needed 5% (95% CI, 1% - 9%; P = 0.01) and 4% (95% CI, 1% - 8%; P = 0.02) lower warfarin dosage, respectively. The warfarin dosage requirement showed no significant difference between GG and GA genotype carriers, P=0.12. Conclusion: Our study showed that GGCX polymorphisms were significantly associated with warfarin dose requirement. These polymorphisms should be considered in future warfarin personalized treatment.

Keywords: GGCX, Warfarin, Polymorphism, Meta-Analysis

1. Introduction

Warfarin is the most widely prescribed oral anticoagulant for reducing thromboembolic events in patients with atrial fibrillation, heart valve replacement, deep vein thrombosis and pulmonary embolism.1-3. However, the existing problems in warfarin clinical application including large individual and ethnic variability in the anticoagulant effect, narrow therapeutic index and serious adverse effects and so on.4-14. In the clinical practice, warfarin dosage needs to be carefully adjusted based on international normalization ratio (INR) and must to be maintained within a therapeutic range.15

Previous studies have identified many clinical, genetic and environmental factors have different effects on the variability of warfarin maintain dose.6-7. And it has also been widely accepted that the reasons for warfarin dose discrepancy are mainly due to genetic factors, among which polymorphism (-1639 G>A) in the drug target vitamin K epoxide reductase complex subunit 1 gene (VKORC1) and polymorphisms (R144C, I359L) of the main warfarin metabolizing gene cytochrome-P450 2C9 (CYP2C9) can explain the most part.8-9

The anticoagulant mechanism of warfarin is by reducing the regeneration of vitamin K hydroquinone from vitamin K epoxide in the vitamin K cycle in the liver.10-11. Post-translational modification of glutamate to gamma carboxyl glutamate is required for the activity of vitamin K-dependent proteins, like factors II, VII, IX, X and protein C, S and Z which are all involved in the coagulation pathway. And the carboxylation effect of these proteins is accomplished by the enzyme gamma-glutamyl carboxylation (GGCX),
which was located in the rough endoplasmic reticulum and Golgi apparatus. It suggested that GGCX paly a key role in Vitamin K cycle.

To data, studies on the association of GGCX polymorphisms with warfarin dosage have been widely explored. However, the results still remain inconclusive and conflicting. The aim of this study is to provide a comprehensive assessment on the association between GGCX polymorphisms and WSD. We collected all available publications on pharmacogenetic studies of the inference of these polymorphisms to warfarin stable dose, and given a quantitatively study using meta-analysis.

2. Materials and Methods

2.1. Search Strategy

All clinical studies on GGCX polymorphisms and warfarin stable dose were identified through systematic searches in PubMed and EMBASE published up to Feb 28, 2014. The search terms were “GGCX” or “gamma-glutamyl carboxylase” in combination with warfarin and “polyorphism” or “genotype” or “mutation”. The reference lists of reviews and retrieved articles were hand searched at the same time.

2.2. Inclusion and Exclusion Criteria

A study was included in the meta-analysis if it was satisfied with following criteria: (1) prospective and retrospective cohort studies, case-control studies and randomized controlled trials were included; (2) genotyping of at least one polymorphism of GGCX, (3) sample size and warfarin maintance dose for each genotypes were displayed. If a study did not supply number or ethnicities of patients, mean maintance dose of warfarin, authors were contacted for additional information;

Studies were excluded if any of the following applied: (1) review articles or case report; (2) The inclusion and exclusion criteria for study patients were undefined; (3) papers written in a language other than English or Chinese;

2.3. Data Extraction

A double-blinded search and identification of eligible articles based on the above inclusion criteria were carried out independently by two researchers (Zhi-Ying Luo and Xiao-Bing Li). The data recording form contains the first author’s name, year of publication, ethnicity (country), number of patents, sex, age (mean and SD), genotype method, target INR range, indication of warfarin and warfarin dose of each genotype. After exacted data were reviewed and compared by a third reviewer (Wei Zhang), and the discrepancies between extractors were discussed and solved with consensus.

If the study provide medians and interquartile ranges or medians and ranges (minimum - maximum) instead of means and SDs, we imputed the means ans SDs as described in Cochrane handbooke and Hozo et al. 12.

2.4. Statistical Methods

The units of warfarin dosage were differently represented as dose/week by some authors and as dose/day by others. In order to uniform the warfarin dosage before meta-analyses, we divided the mean dose and associated SD in each genotype group by the mean stable dose in the reference groups 13-15. The warfarin dosage of rs699664GG and rs12714145GG genotypes were used as the reference, respectively.

The STATA 12.0 software (StataCorp, College Station, TX, USA) and Revman 5.0 (Cochrane Collaboration) were applied to analyze the relationships between the polymorphisms and warfarin stable dose. The weight of each study is the inverse of its SD of normalized warfarin dose, and the calculation of mean difference (MD). After normalized, the calculated MDs representen relative differences rather than absolute differences in stable dose. For example, a mean difference of 0.1 would indicate a 10% increase in warfarin dose requirement. The indicator of effect used weight mean difference (WMD), and sum of each WMD total WMD. The impact of gene polymorphisms on warfarin stable dose was examined by means of Z test, and the significant level was set as a P value less than 0.05.

The heterogeneity of publications in each meta-analysis was evaluated by Mantel-Haenszel chi-squared test (Cochran’s Q test) and calculation of the variation across studies attributable to heterogeneity. If the Cochran Q test P value <0.1, the random-effect model was chosen to calculate the overall MD, otherwise a fix-effect model was used. To further evaluate the extent of heterogeneity between publications, (I²) test was employed, and the values of (I²) different levels (25%, 50%, 75%) were considered as low, moderate and high heterogeneity, respectively.

In order to eliminate the sources of heterogeneity, we conducted the sensitive analysis by deselecting studies one by one in chronological order. We conducted this procedure by removing one study and the rest were analyzed to evaluate whether the results were affected statistically significantly. Publication bias was examined by means of Funnel Plot where normalized dose requirement were plotted versus inverse standard error. To further evaluate publication bias, Begg’s and Egger’s test were also used in this study.

3. Results

3.1. Studies Identification and Characteristics

We identified 56 published studies with full-text articles examined the relationship between GGCX polymorphisms and warfarin dosage. Of these, only 14 studies were included in the meta-analysis. Maong the included studies, ten of which investigated the effect of GGCX rs699664 polymorphism on warfarin dosage were included, and four studies about the effect of rs12714145 on warfarin dose were included. A flow chart summarizing the process of study inclusion/exclusion was depicted in Figure 1. A summary of the all included studies was given in Table 1. A total of 4167 patients were
3.2. Meta-Analysis

3.2.1. Impact of GGCX Gene rs699664 on Warfarin Dosage

The influence of GGCX rs699664 on warfarin dosage requirement was shown in figure 2. The total number of patients carrying GG, GA and AA genotypes were 1084, 1078 and 298 respectively. Comparing to rs699664AA genotype carriers, rs699664GG genotype carriers required higher 3% [95% CI: 2% - 4%, P-value < 0.0001] warfarin dose. The warfarin dosage requirement showed no significant difference between rs699664GG and rs699664GA genotype carriers, P=0.51. The analysis of GG vs AA shows homogeneity (P = 0.09, $I^2 = 40\%$), so fixed-effect model was used. Random-effect mode was chosen in this analysis of GG vs GA because of the statistic heterogeneity (P = 0.00, $I^2 = 83\%$).

![Flow chart](image)

**Figure 1.** Flow chart of screening excluded studies and its reasons, identified the studies in final analysis.

**Table 1.** Characteristics of included studies.

<table>
<thead>
<tr>
<th>Studies</th>
<th>Study location or population</th>
<th>Number</th>
<th>Age</th>
<th>INR target range</th>
<th>Indication of warfarin</th>
<th>GGCX genotype frequencies rs12714145 (N)</th>
<th>rs699664 (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shen-Wen Huang, 2011</td>
<td>Chinese (Asian)</td>
<td>217(90/127)</td>
<td>58±16</td>
<td>1.8-3.0</td>
<td>VTD</td>
<td>GG 84, GA 117, AA 16</td>
<td>-</td>
</tr>
<tr>
<td>Larisa H, 2012</td>
<td>African Americans</td>
<td>338(98/240)</td>
<td>58±16</td>
<td>NR</td>
<td>NR</td>
<td>71, 107, 33</td>
<td>46, 92, 70</td>
</tr>
<tr>
<td>Kyung-Eun Lee, 2012</td>
<td>Korean (Asian)</td>
<td>191(63/128)</td>
<td>57.8±10.1</td>
<td>2.0-3.0</td>
<td>HVR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jung Ran Choi, 2011</td>
<td>Korean (Asian)</td>
<td>564(306/258)</td>
<td>63.2±11.7</td>
<td>2.0-3.0</td>
<td>AF, HVR, PE, DVT</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cristi R. King, 2010</td>
<td>Caucasian</td>
<td>985(486/499)</td>
<td>60±15</td>
<td>1.5-2.0</td>
<td>VTE</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hedi Schelleman, 2010</td>
<td>African Americans</td>
<td>22(9/13)</td>
<td>NR</td>
<td>2.0-3.0</td>
<td>VTE</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Masako Ohno, 2009</td>
<td>Japanese (Asian)</td>
<td>125(75/50)</td>
<td>73.1±11.6</td>
<td>1.5-3.0</td>
<td>AF, DVT, PE</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rina Kimura, 2007</td>
<td>Japanese (Asian)</td>
<td>93</td>
<td>68.1±10.6</td>
<td>1.6-2.6</td>
<td>CEI, E</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manuela Vesci, 2006</td>
<td>Israel</td>
<td>100(52/48)</td>
<td>62 (18-88)</td>
<td>1.9-4.2</td>
<td>NR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ronen Loebstein, 2005</td>
<td>Israel</td>
<td>100(52/48)</td>
<td>62 (18-88)</td>
<td>1.9-4.2</td>
<td>NR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Huang SW, 2011</td>
<td>Chinese (Asian)</td>
<td>249(111/138)</td>
<td>51.4±14.9</td>
<td>1.8-3.0</td>
<td>AF</td>
<td>97, 134, 18</td>
<td>-</td>
</tr>
<tr>
<td>Yundan Liang, 2013</td>
<td>Chinese (Asian)</td>
<td>300(138/162)</td>
<td>47.9±12.5</td>
<td>1.5-3.0</td>
<td>HVR, DVT, CABG</td>
<td>104, 146, 33</td>
<td>119, 137, 24</td>
</tr>
<tr>
<td>Shi-Long Zhong, 2011</td>
<td>Chinese (Asian)</td>
<td>845(478/367)</td>
<td>47.9(38.9-55.8)</td>
<td>1.8-3.0</td>
<td>HVR</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Note: DVT = Deep Vein Thrombosis, NR = Not Referred, HVR = Heart Valve Replacement, AF = Atrial Fibrillation, VTE = Venous Thromboembolism, CABG = Coronary Artery Bypass Graft, PE = Pulmonary Embolism, MI = Myocardial infarction, ASO = Arteriosclerosis obliterans, AV = Artificial vessel, CEI = Cardioembolic infarction, EI = Embolic infarction
3.2.2. Impact of GGCX rs12714145 Polymorphism on Warfarin Dosage Requirement

The impact of GGCX rs12714145 polymorphism on warfarin dose requirement was described in Fig 3. Only 4 publications were included in our study with pooled data of 649 patients (356 GG, 405 GA and 100 AA respectively). No statistic heterogeneities were found through meta-analyses. Compared to GG and GA genotype carriers, AA carriers needed 5% (95% CI, 1% - 9%; P = 0.01) and 4% (95% CI, 1% - 9%; P = 0.01) higher warfarin dosage. The warfarin dosage requirement showed no significant difference between GG and GA genotype carriers, P=0.12.

![Figure 3. Forest plot of the impact of GGCX rs12714145 polymorphism on warfarin dose requirement.](image-url)
3.2.3. Sensitive Analysis and Publication Bias

All meta-analyses about GGCX rs699664 polymorphism and warfarin dose requirement showed evidence of statistical heterogeneity, and a random-effects model was used in these meta-analyses. We first conducted the sensitive analyses by deselecting studies one by one in chronological order, and found no significant difference or reversal change between these studies and original outcomes.

We also conducted subgroup analyses according to population diversities if statistic heterogeneity was found. For all of these meta-analyses conducted in this study, only the compare between GGCX rs699664GG and GA genotypes showed significant statistic heterogeneity. Of the 10 included studies about the relationship between rs699664GG and GA polymorphism and warfarin dose requirement, only one study presented the effect in Caucasian population, so the subgroup analysis was not carried out in this category. More than two studies had been performed in each subgroup. The warfarin dosage showed no significant difference between rs699664GG and rs699664GA genotype carriers either in African-American or Asian population, like shown in Table 2. Because of statistic heterogeneity in the Asian population group, a further subgroup was conducted in these studies according to country diversities. And results showed that GGCX rs699664 GG genotypes need higher 0.17 (95% CI: 0.07 - 0.27, P=0.01) warfarin than GA genotypes.

Funnel plots of each analysis did not indicate any asymmetries suggestive of publication bias (data not shown).

<table>
<thead>
<tr>
<th>Subgroups</th>
<th>Number</th>
<th>Heterogeneity P</th>
<th>I²</th>
<th>Mean difference (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African-American</td>
<td>2</td>
<td>0.32</td>
<td>0%</td>
<td>-0.04 (-0.01, 0.03)</td>
<td>0.32</td>
</tr>
<tr>
<td>Asian</td>
<td>7</td>
<td>0.00</td>
<td>88%</td>
<td>0.03 (-0.04, 0.09)</td>
<td>0.42</td>
</tr>
<tr>
<td>Country</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chinese</td>
<td>2</td>
<td>0.04</td>
<td>77%</td>
<td>0.07 (-0.08, 0.21)</td>
<td>0.37</td>
</tr>
<tr>
<td>Japnese</td>
<td>2</td>
<td>0.57</td>
<td>0%</td>
<td>0.17 (0.07, 0.27)</td>
<td>0.01</td>
</tr>
<tr>
<td>Korean</td>
<td>2</td>
<td>0.00</td>
<td>90%</td>
<td>-0.04 (-0.18, 0.11)</td>
<td>0.61</td>
</tr>
</tbody>
</table>

Table 2. Warfarin dosage requirement between GGCX rs699664 GG vs GA genotypes in different populations.

4. Discussion

The aim of this meta-analysis was to identify whether GGCX polymorphisms had a potential effect on warfarin dosage. The results of our meta-analysis suggested that GGCX rs699664AA carriers need lower warfarin dosage than wild homozygous(GG) carriers, and GGCX rs12714145AA carriers required higher warfarin dose than GG and GA genotype carriers.

Polymorphism of GGCX gene was first reported associated with rare autosomal recessive bleeding disorders by Brenner B et al. in 1998, and the further animal experiment further provided clear proof of the key role of GGCX for the functon of these Vitamin K-dependent potroiens. GGCX rs699664 polymorphism was a demonstrated functional mutation, which causes a missense change R325Q. The results of our analyses showed that 699664 GG carriers need higher dosage than AA carriers, and the results of subgroup analyses demonstrated that the GGCX rs699664GG genotypes had higher warfarin dose requirement than GG and GA genotypes carriers. Wadelius et al. has reported that many GGCX single nucleotide polymorphisms (SNPs) are in high disequilibrium linkage (LD) in Caucasian population. And we hypothesis that other functional SNPs may be in high LD with GGCX.

All of the meta-analyses on the two polymorphisms of GGCX with confirmed association with warfarin stable dose showed no study bias, which means the results are reliable. In addition, in the sensitive analyses conducted in our study showed no statistic changes or reversal results by deselecting studies one by one in chronological order, which means the result of present meta-analyses were stable.

The clinical use of warfarin is always a challenge to doctors and researcher. Nevertheless, the era of using one standard fixed dose for all patients is be replaced by personalized warfarin treatment because of breakthroughs in the pharmacogenetics studies of warfarin. Even though warfarin dosage inter-individual and inter-ethnicity difference can be mainly explained by VKORC1 and CYP2C9 gene polymorphisms, other factors, including age, gender, body mass index, health conditions, co-medications and so on , also had important influence on warfarin sensitive. Other genes such as summarized in this study that might have important role in warfarin dose variation are being characterized.

The main limitation of our meta-analysis is that the warfarin mean dosages applied to our meta-analysis have not been adjusted for other genetic and non-genetic predictors of dose as described above. The other is that data of some study was presented as figures or not able to acquire the mean warfarin dose.

This is the first meta-analysis about the impact of GGCX...
responsibility for the decision to submit the report. All the authors had complete access to the data and have full responsibility for the decision to submit the report.

Acknowledgments

This work was supported by the National Scientific Foundation of China (No. 81273595, 30901834, 81001476), the Scientific Foundation of Hunan (No. 11K073, 10J J4020), the “863” Project (No. 2012AA02A518) and NCET-10-0843.

Foundation of China (No. 81273595, 30901834, 81001476) and NCET-10-0843. All the authors had complete access to the data and have full responsibility for the decision to submit the report.

References


